key: cord-1029977-dnyhhnxn
authors: Della-Torre, Emanuel; Lanzillotta, Marco; Ramirez, Giuseppe Alvise; Dagna, Lorenzo; Tresoldi, Moreno
title: Serum IgG4 elevation in hyper-inflamed COVID-19 patients. Author's reply
date: 2021-10-22
journal: Eur J Intern Med
DOI: 10.1016/j.ejim.2021.10.025
sha: 4f6589f9b6acf557539d60e959f15d36cd6c9a8e
doc_id: 1029977
cord_uid: dnyhhnxn

nan

CONTRIBUTORSHIP -All authors contributed to acquisition, analysis and interpretation of data. All authors revised the work critically for important intellectual content and approved the 2 final version of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Hospital Ethical Committee (no. 34/int/2020).

The authors agree to share the data generated by the present research and to make them openly and publicly available upon publication. [1, 2] . In particular, we agree that serum IgG4 levels may vary significantly in healthy individuals and in various inflammatory and allergic diseases [3, 4] . We also recognize, as acknowledged in the discussion, that the limited number of patients included in the study does not allow definitive conclusions about the practical utility of our

findings. Yet, collecting informative blood samples was quite challenging because most patients referred to our hospital during the second pandemic wave of COVID-19 were already on medium/high dose glucocorticoids as part of their domiciliary therapy, a treatment regimen that typically rapidly affects serum IgG subclasses concentration [5] . Despite these limitations, we were able to assemble an informative cohort of COVID-19 patients and to return statistically production of IgG4 antibodies [6] [7] [8] . Indeed, IgG4 elevation in the context of high IL-6 levels has been already reported in other inflammatory disorders such as Castelman's disease,

suggesting that the increase of serum IgG4 observed in hyper-inflamed COVID-19 patients more likely represents an intrinsic disease feature rather than an occasional finding related to other causes [3] . Still, due to the lack of additional mechanistic studies, our preliminary and correlative observations clearly deserve further investigation.

Serum IgG4 level predicts COVID-19 related mortality

Disguised aspects of IgG4

Treating life-threatening TAFRO syndrome with interleukin-1 inhibition

Advances in the diagnosis and management of IgG4 related disease

Effects of Systemically Administered Hydrocortisone on the Human Immunome

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4+ T cells